Product Overview
[Drug Name]
Generic Name: Candesartan Cilexetil and Hydrochlorothiazide Tablets
Trade Name: Bo Kai Qing
English Name: Candesartan Cilexetil and Hydrochlorothiazide Tablets
Chinese Pinyin: KanDeQingSaiPian
[Appearance]
This product is a light pink, oval tablet with a central score.
[Indications]
For the treatment of hypertension. This product is not indicated for the initial treatment of hypertension. It is indicated for adults with essential hypertension whose blood pressure is not effectively controlled with candesartan cilexetil or hydrochlorothiazide alone, or as an alternative treatment for candesartan cilexetil and hydrochlorothiazide combined at the same dose.
[Dosage and Administration]
The recommended dose is one tablet once daily, taken orally, on an empty stomach or with a meal. The antihypertensive effect is generally seen within four weeks of starting treatment. Candesartan Cilexetil and Hydrochlorothiazide tablets can be used when blood pressure is not effectively controlled with candesartan cilexetil or hydrochlorothiazide alone. It is recommended that, before initiating combination therapy, the dose of either component (candesartan cilexetil or hydrochlorothiazide) be gradually adjusted based on the degree of blood pressure reduction achieved. This product is contraindicated in patients with severe renal insufficiency, severe hepatic insufficiency, and/or cholestasis. If necessary, this product can be used in combination with other antihypertensive drugs. No dosage adjustment is required for elderly patients.
[Adverse Reactions]
Common adverse reactions include upper respiratory tract infection; systemic reactions: back pain; cold-like symptoms; dizziness, headache, etc.
[Contraindications]
1. This product is contraindicated in patients who are allergic to any component of this product.
2. Because this product contains hydrochlorothiazide, it is contraindicated in patients with anuria or allergies to other sulfonamides.
3. This product is contraindicated in women who are pregnant or planning pregnancy.
4. This product is contraindicated in patients with severe renal insufficiency.
5. This product is contraindicated in patients with severe hepatic insufficiency and/or cholestasis.
6. This product is contraindicated in patients with refractory hypokalemia and hypercalcemia.
7. This product is contraindicated in patients with gout.
[Precautions]
1. Breastfeeding women should avoid taking this product. If necessary, breastfeeding should be discontinued. 2. Patients with hyponatremia and/or hypovolemia should correct these conditions before starting treatment. Otherwise, this product should be taken under close monitoring. If hypotension occurs, emergency measures should be taken. 3. Patients taking this product may experience hypotension during major surgery and anesthesia. 4. In patients with impaired liver function or chronic liver disease, even minor changes in fluid and electrolyte balance may lead to hepatic coma. Therefore, this product should be used with caution in such patients. 5. If necessary, electrolytes should be monitored regularly during treatment with this product, and electrolyte imbalances should be corrected proactively. 6. Some patients may experience hyperuricemia or acute gout attacks while receiving thiazide therapy, or may experience elevated cholesterol and triglyceride levels, or hypomagnesemia. 7. Diabetic patients may need to adjust their insulin or oral hypoglycemic doses when taking this product. 8. Allergic reactions to hydrochlorothiazide may occur with this product, especially in patients with a history of allergies or bronchial asthma. 9. The hydrochlorothiazide in this product may induce or worsen systemic lupus erythematosus flare-ups. 10. This product should not be taken concurrently with lithium preparations. 11. This product should be discontinued before parathyroid function testing.
[Use in Special Populations]
Precautions for Children:
Currently, there are no safety and efficacy data for this product in children.
Precautions for Pregnancy and Lactation:
This product is contraindicated in women who are pregnant or planning pregnancy. Precautions for Elderly Patients:
In clinical studies, this product showed no difference in efficacy and safety between elderly patients (≥65 years) and younger patients (<65 years). However, some elderly individuals may be more sensitive to the drug. Hydrochlorothiazide is primarily excreted through the kidneys, so patients with renal insufficiency are more likely to experience drug toxicity and side effects.
[Drug Interactions]
Drug interactions may occur if used concomitantly with other medications. Please consult your physician or pharmacist for details.
[Pharmacological Actions]
Candesartan is a combination drug consisting of the angiotensin II receptor antagonist candesartan and the thiazide diuretic hydrochlorothiazide. It exhibits a synergistic antihypertensive effect that is more effective than either component alone. Candesartan selectively blocks the binding of angiotensin II to AT1 receptors in various organs and tissues, such as vascular smooth muscle and the adrenal glands, thereby blocking the pharmacological effects of angiotensin II. Candesartan does not inhibit angiotensin-converting enzyme (ACE), which degrades bradykinin into inactive metabolites, and therefore does not increase bradykinin levels in the body.
[Storage]
Keep sealed.
[Packaging]
8mg/12.5mg x 14 tablets
[Expiry Date]
24 months
[Approval Number]
National Medicine Standard No. H20110127
[Manufacturer]
Company Name: Jiangsu Deyuan Pharmaceutical Co., Ltd.
